| This report contains COVID-19 specific updates.
Global Markets for Bioengineered Protein Drugs
Report Highlights
The global market for bioengineered protein drugs is estimated to increase from $354.1 billion in 2022 to reach $521.3 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.
Report Includes
- 28 data tables and 23 additional tables
- An up-to-date overview and analysis of the global markets for bioengineered protein drugs
- Analyses of the global market trends, with historic market revenue data (sales figures) from 2019-2021, estimates for 2022, forecasts for 2023, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the emerging technology trends, opportunities and gaps estimating current and future demand for bioengineered protein drugs market, and major regions and countries involved in market developments
- Estimation of the actual market size and revenue forecast for global bioengineered protein drugs market in USD million terms, and corresponding market share analysis by drug type, disease type, and region
- In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall biopharmaceutical industry
- Discussion of the regulatory aspects and standards for bioengineered protein therapeutics, newly approved products, underlying clinical trials for all phases and list of vaccines, and the COVID-19 impact on the progress of this market
- Insight into the recent industry structure, competitive aspects of each product segment, increasing investment on R&D activities to develop new and improved therapies, market development strategies, and company value share analysis
- Identification of the major companies involved in the production and modification of protein drugs, and analysis of the company competitive landscape based on their recent developments, financial performance, and segmental revenues
- Descriptive company profiles of the leading global players, including AbbVie Inc., AstraZeneca plc, GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS) Co., Pfizer Inc., Merck and Co., and Sanofi S.A.
Report Scope
This report aims to provide a comprehensive study of the global market for bioengineered protein drugs, both in terms of quantitative and qualitative data, to help readers develop business/growth strategies, assess the market landscape, analyze their position in the current marketplace and make informed business decisions regarding bioengineered protein drugs. Segmentation is based on the drug type, disease type, and region.
Industry growth drivers, restraints, trends, and opportunities in bioengineered protein drugs are also discussed in detail. The report also provides information on the bioengineered protein drug market competitive landscape, features detailed company profiles, and discusses the impact of COVID-19 on the market.
Frequently Asked Questions (FAQs)
- A growing and aging population,
- Increasing prevalence of chronic diseases,
- Advancements in manufacturing technologies,
- New product launches and label expansions,
- Premium pricing for innovative drugs and
- Growing demand in emerging markets
Analyst Credentials
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.
Report Synopsis
| Report Metrics | Details | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2021 | |||||||||||||||||||||
| Forecast period considered | 2022-2027 | |||||||||||||||||||||
| Base year market size | $327.6 billion | |||||||||||||||||||||
| Market size forecast | $521.3 billion | |||||||||||||||||||||
| Growth rate | CAGR of 8.0% for the forecast period of 2022-2027 | |||||||||||||||||||||
| Units considered | $ Millions | |||||||||||||||||||||
| Segments covered | By Drug Type, Disease Type, and Region | |||||||||||||||||||||
| Regions covered | North America, Europe, and Emerging markets | |||||||||||||||||||||
| Key Market Drivers |
|
|||||||||||||||||||||
| Companies studied |
|
Report Highlights
The global market for bioengineered protein drugs is expected to reach $228.4 billion by 2021 from $172.5 billion in 2016, rising at a compound annual growth rate (CAGR) of 5.8% from 2016 through 2021.
Report Includes
- An overview of the global market for bioengineered protein drugs.
- Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials.
- A look at current technologies underlying the market as well as the effects new technologies will have on the market.
- An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
- Profiles major companies involved in the production and modification of protein drugs.
Report Highlights
The global market for bioengineered protein drugs was valued at $151.9 billion in 2013 and will reach about $157.0 billion in 2014. The market is further expected to grow to about $222.7 billion in 2019, a compound annual growth rate (CAGR) of 7.2% from 2014 through 2019.
Report Includes
- An overview of the global market for bioengineered protein drugs.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials.
- A look at current technologies underlying the market as well as the effects new technologies will have on the market.
- An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
- Profiles of the major companies involved in the production and modification of protein drugs.
Report Highlights
-
The total global market for protein drugs was $47.4 billion in 2006. The market will reach $55.7 billion by the end of 2011, an average annual growth rate (AAGR) of 3.3%.
-
Modified and engineered antibodies present the largest share of the total global market. In 2006, this sector held almost 56% of the global market. By the end of 2011 its share will drop slightly but not significantly to 54%.
-
Hormone protein drugs have the largest AAGR through the forecast period, averaging 5.1% through 2011 to reach $11.9 billion by 2011.
Report Highlights
-
In 2002, drug companies sold nearly $33 billion in protein drugs, and they are projected to approach $40 billion in 2003.
-
Rising at an average annual growth rate (AAGR) of 12.2%, this market is expected to reach $71 billion in 2008.
-
Replacement proteins constitute the bulk of the market and will rise at an AAGR of 9.8% from $31.4 billion in 2003 to $50 billion in 2008.
-
Monoclonal antibodies and fusion proteins will rise from $8.5 billion in 2003 to $20.1 billion in 2008.
-
These products effectively strip market share from older, less effective therapies. Most notably, a number of monoclonal antibodies are in the last stages of clinical trials for the treatment of autoimmune disease and cancer and promise to be blockbuster products.